Cross-talk between the proto-oncogenes Met and Ron - PubMed (original) (raw)
. 2000 Jun 22;19(27):3041-9.
doi: 10.1038/sj.onc.1203620.
Affiliations
- PMID: 10871856
- DOI: 10.1038/sj.onc.1203620
Cross-talk between the proto-oncogenes Met and Ron
A Follenzi et al. Oncogene. 2000.
Abstract
Scatter Factors control a complex genetic program known as 'invasive growth'. HGF (Scatter factor 1) and MSP (Scatter Factor 2) bind to tyrosine kinase receptors encoded by the proto-oncogenes MET and RON. Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Ron, and vice versa. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). The transphosphorylation specifically takes place for the receptor subfamily, as it is not observed between Met or Ron and ErbB1, ErbB2 or TrkA. Cross-linking experiments show that non-covalent Met-Ron complexes are present on the cell surface, before ligand-induced dimerization. Co-expression of a kinase inactive Ron receptor with naturally-occurring oncogenic Met mutants suppresses the transforming phenotype, suggesting a dominant negative role for the inefficient kinase partner. These data show that, while specific for their ligands, scatter factor receptors cross-talk and cooperate in intracellular signaling.
Similar articles
- MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA, Longati P, Pugliese L, Gual P, Bardelli A, Michieli P. Williams TA, et al. J Cell Physiol. 1999 Dec;181(3):507-14. doi: 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q. J Cell Physiol. 1999. PMID: 10528237 - Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM. Benvenuti S, et al. Cancer Res. 2011 Mar 1;71(5):1945-55. doi: 10.1158/0008-5472.CAN-10-2100. Epub 2011 Jan 6. Cancer Res. 2011. PMID: 21212418 - Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.
Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ. Danilkovitch-Miagkova A, et al. Mol Cell Biol. 2001 Sep;21(17):5857-68. doi: 10.1128/MCB.21.17.5857-5868.2001. Mol Cell Biol. 2001. PMID: 11486025 Free PMC article. - Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.
Danilkovitch-Miagkova A, Leonard EJ. Danilkovitch-Miagkova A, et al. Histol Histopathol. 2001 Apr;16(2):623-31. doi: 10.14670/HH-16.623. Histol Histopathol. 2001. PMID: 11332718 Review.
Cited by
- Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG. Zou Y, et al. PLoS One. 2013 Jul 29;8(7):e69992. doi: 10.1371/journal.pone.0069992. Print 2013. PLoS One. 2013. PMID: 23922886 Free PMC article. - Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Kawada I, et al. Cancer Res. 2014 Feb 1;74(3):884-95. doi: 10.1158/0008-5472.CAN-12-3583. Epub 2013 Dec 4. Cancer Res. 2014. PMID: 24305878 Free PMC article. - Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.
Chen JF, Yu BX, Yu R, Ma L, Lv XY, Cheng Y, Ma Q. Chen JF, et al. Oncol Rep. 2017 Feb;37(2):721-728. doi: 10.3892/or.2017.5356. Epub 2017 Jan 5. Oncol Rep. 2017. PMID: 28075465 Free PMC article. - Macrophage-Stimulating Protein Enhances Osteoblastic Differentiation via the Recepteur d'Origine Nantais Receptor and Extracellular Signal-Regulated Kinase Signaling Pathway.
Jeong BC, Oh SH, Lee MN, Koh JT. Jeong BC, et al. J Bone Metab. 2020 Nov;27(4):267-279. doi: 10.11005/jbm.2020.27.4.267. Epub 2020 Nov 30. J Bone Metab. 2020. PMID: 33317230 Free PMC article. - Loss of Ron receptor signaling leads to reduced obesity, diabetic phenotypes and hepatic steatosis in response to high-fat diet in mice.
Stuart WD, Brown NE, Paluch AM, Waltz SE. Stuart WD, et al. Am J Physiol Endocrinol Metab. 2015 Apr 1;308(7):E562-72. doi: 10.1152/ajpendo.00467.2014. Epub 2015 Feb 3. Am J Physiol Endocrinol Metab. 2015. PMID: 25648832 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous